FDA OTC Drug Evaluation Director Gilbertson informs Procter & Gamble that a study on psyllium as a cholesterol-lowering agent proposed in a March 23 letter appears to "provide adequate data for statistical analysis of endpoint efficacy and safety variables, dietary and test drug compliance data." However, Gilbertson notes that the study will not provide information on dose response or the mechanism of action, two questions of interest to FDA.
You may also be interested in...
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
The US FDA wants manufacturers and compounding facilities to test drug products for methanol in alcohol ingredients, and responds to reports of fatal methanol poisonings of consumers who ingested alcohol-based based hand sanitizers.